Hydroxychloroquine
- TRADE NAMES: Ercoquin; Oxiklorin; Plaquenil (Sanofi-Aventis); Plaquinol; Quensyl; Toremonil; Yuma
- INDICATIONS: Malaria, lupus erythematosus, rheumatoid arthritis
- CLASS: Antimalarial, Antimicrobial, Antiprotozoal, Covid-19 putative drug, Disease-modifying antirheumatic drug (DMARD)
- HALF-LIFE: 32–50 days
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Chloroquine, Cholestyramine, Dapsone, Droperidol, Ethosuximide, Lacosamide, Lanthanum, Moxifloxacin, Neostigmine, Oxcarbazepine, Penicillamine, Tiagabine, Typhoid Vaccine, Vigabatrin, Yellow Fever Vaccine
PREGNANCY CATEGORY: C
Investigated for treating COVID-19.
Please login to see the rest of this drug profile
SKIN.
HAIR.
NAILS.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
OCULAR.
OTIC.
RENAL.
RESPIRATORY.
OTHER.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of hydroxychloroquine in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 01/21/2024
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric